Jci_page_head_homepage_01 Jci_page_head_homepage_02
David M. Selva, Kevin N. Hogeveen, Sheila M. Innis, Geoffrey L. Hammond
Published in Volume 117, Issue 12
J Clin Invest. 2007; 117(12):3979–3987 doi:10.1172/JCI32249
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 3
Monosaccharides decrease human SHBG production by HepG2 cells in concert with reduced cellular HNF-4α levels.

(A) Human SHBG accumulation in the medium of HepG2 cells treated daily with 10 mM of glucose or fructose was substantially reduced. Data points are shown as mean ± SD of triplicates; **P < 0.01 compared with no glucose/fructose supplementation. (B) Human SHBG and HNF-4α mRNA levels determined by RT-PCR in HepG2 cells cultured for 5 days as in A. Cyclophilin A (CypA) mRNA was amplified as in internal control. (C) HNF-4α and cyclophilin A levels measured by Western blotting in HepG2 cells cultured for 5 days as in B. (D) Human SHBG promoter activity was measured in the context of a luciferase reporter gene assay in HepG2 cells cultured for 4 days in the presence or absence of 10 mM glucose or fructose. Data points are shown as mean ± SD of triplicates; **P < 0.01 compared with no glucose/fructose supplementation.